MedPath

A romdomized controlled study of effectiveness between transcatheter arterial chemoembolization with cisplatin and transcatheter arterial chemoembolization with epirubicin for multiple hepatocellular carcinomas

Phase 2
Conditions
multiple hepatocellar carcinomas
Registration Number
JPRN-UMIN000003162
Lead Sponsor
Department of Surgery, Graduate School of Medicine Kyoto Uinversity
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
160
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with another active cancer 2)Patients with extrahepatic metastasis 3)Patients with prior surgical reconstruction of the biliary tract or prior endoscopic treatment of ampulla of vater 4)Patients with clinically significant refractory ascites or pleural effusion 5)Patients with hepatic encephalopathy 6)Patients with severe co-morbidity such as cardiac failure and renal failure 7) Patients who have taken doses of chemotherapeutic agents with cardiac toxicity exceeding a set threshold. 8)Patients with a medical history of severe hypersensitivity 9)Patients who are pregnant, lactating or are suspected to be pregnant. 10)Patients who are concluded to be inappropriate to participate in this study by their physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate(based on EASL criteria)
Secondary Outcome Measures
NameTimeMethod
Overall survival Progression free survival Response rate(based on the General Rules for the Clinical and Pathological Study of Primary Liver Cancer) Safety
© Copyright 2025. All Rights Reserved by MedPath